Astellas Pharma US, Inc. To Pay $7.3 Million To Resolve False Claims Act Allegations
PHILADELPHIA - Pharmaceutical company Astellas Pharma US, Inc., will pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promoting of the drug Mycamine for pediatric use. The settlement was announced today by United States Attorney Zane David Memeger and the Justice Department. Astellas Pharma US, Inc., located in Northbrook, Illinois, manufactures and sells pharmaceutical drugs, including Mycamine.
- Date:April 16, 2014
- Agency:U.S. Attorney
- Criminal and Civil Actions